SCHEMBL4675261

SCHEMBL4675261

O=C(Cc1ccsc1-c1ccccc1)C(=O)c1nc[nH]n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.50
ALOX15 P16050 1/20 0.50
MAPK1 P28482 1/20 0.50
KMT2A Q03164 1/20 0.50
KDM4E B2RXH2 1/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.35
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
THRB P10828 1/20 0.32
HPGD P15428 1/20 0.32
PTPN1 P18031 2/20 0.31
TRPM8 Q7Z2W7 1/20 0.31
MAPK8 P45983 1/20 0.31
PTPRC P08575 1/20 0.31
PTPN2 P17706 1/20 0.31
PTGS2 P35354 1/20 0.31
ERCC5 P28715 1/20 0.31
FEN1 P39748 1/20 0.31
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27555974 0.85 TP53 (0.36) TP53ALOX15MAPK1KMT2AKDM4E
SCHEMBL27578549 0.84 HPGD (0.34) TP53ALOX15MAPK1KMT2AKDM4E
SCHEMBL4672601 0.81 LTB4R (0.34) TP53ALOX15MAPK1KMT2ASMN1; SMN2
SCHEMBL4675519 0.81 PTGDR2 (0.40) TP53ALOX15MAPK1KMT2AKDM4E
SCHEMBL4674626 0.81 TP53 (0.50) TP53ALOX15MAPK1KMT2AKDM4E
SCHEMBL4674281 0.80 RAB9A (0.32) TP53KMT2AKDM4EPTGDR2NPC1
SCHEMBL4676736 0.79 POLB (0.37) MAPK1KMT2ARAB9AALDH1A1HSD17B10
SCHEMBL4677482 0.79 LTB4R (0.34) TP53ALOX15MAPK1KMT2ASMN1; SMN2
SCHEMBL4677157 0.78 PTGS2 (0.33) MAPK1PTGDR2PTGS2ERCC5FEN1
SCHEMBL4675774 0.76 KDM4E (0.36) MAPK1KMT2AKDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 TP53 999/4885ALOX15 3778/4885MAPK1 2560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.